Pharmaresources: Announcement on the passive reaching of 5% shareholder holdings ratio and equity changes.
Pharmaresources: Simplified Equity Change Report
Pharmaresources: Announcement on adjusting the upper limit of share repurchase price after implementation of annual equity distribution in 2023.
Pharmaresources: Announcement of Annual Equity Distribution Implementation in 2023
Pharmaresources: Announcement on the progress of repurchasing the company's shares to reach 1% of the proportion.
Pharmaresources: Announcement on the lifting of the shareholder's equity pledge.
Pharmaresources: Announcement regarding the progress of repurchasing company shares.
Pharmaresources: Simplified Statement of Changes in Equity
Pharmaresources: An indicative announcement on shareholders' holdings of 5% or more reducing their holdings to less than 5% and changes in equity
Pharmaresources: 2023 Annual Results Briefing Event Schedule
Pharmaresources: Legal Opinion of Beijing Jiayuan Law Firm on the 2023 Annual General Meeting of Shareholders of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.
Pharmaresources: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Pharmaresources: Announcement on holding the 2023 online results briefing
Pharmaresources: CITIC Securities Co., Ltd.'s 2023 follow-up report on Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.
Pharmaresources: Report by CITIC Securities Co., Ltd. on the continuous supervision and training of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. in 2023
Pharmaresources: CITIC Securities Co., Ltd. report on the 2023 continuous supervision and regular on-site inspection report of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.
Pharmaresources: Announcement on the progress of the repurchase of company shares
Pharmaresources: Announcement on shareholders holding 5% or more of the company's shares to reduce their holdings by 1% and the completion of the plan to reduce their holdings
Pharmaresources: Pre-disclosure announcement on plans to reduce shareholders' holdings of 5% or more
Pharmaresources: 2024 First Quarter Report
No Data